title: Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
abstract: BACKGROUND
  The natural history of castration-resistant nonmetastatic prostate cancer is poorly defined.
  
  
  METHODS
  The authors used data from 331 subjects in the placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time to first bone metastases in men with prostate cancer, rising prostate-specific antigen (PSA) despite androgen deprivation therapy, and no radiographic evidence of metastases. Relations between baseline covariates and clinical outcomes were assessed by Cox proportional hazard analyses. Covariates in the model were age, body mass index, prior prostatectomy, prior orchiectomy, Gleason score, performance status, PSA, urinary N-telopeptide, bone alkaline phosphatase, albumin, lactate dehydrogenase, and hemoglobin.
  
  
  RESULTS
  At 2 years, 46% of subjects had developed bone metastases, and 20% had died. Median bone metastasis-free survival was 25 months. In multivariate analyses, baseline PSA ≥ 13.1 ng/mL was associated with shorter overall survival (relative risk [RR], 2.34; 95% confidence interval [CI], 1.71-3.21; P < .0001), time to first bone metastasis (RR, 1.98; 95% CI, 1.43-2.74; P < .0001), and bone metastasis-free survival (RR, 1.98; 95% CI, 1.45-2.70; P < .0001). PSA velocity was significantly associated with overall and bone metastasis-free survival. Other covariates were not consistently associated with clinical outcomes.
  
  
  CONCLUSIONS
  In men with progressive castration-resistant prostate cancer and no detectable metastases, baseline PSA was significantly associated with time to first bone metastasis, bone metastasis-free survival, and overall survival. Other disease and host characteristics, including body mass index and bone turnover markers, were not consistently associated with clinical outcomes.
authors.affiliation: Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. smith.matthew@mgh.harvard.edu.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.forename: Richard
authors.initials: R
authors.lastname: Cook
authors.forename: Ker-Ai
authors.initials: KA
authors.lastname: Lee
authors.forename: Joel B
authors.initials: JB
authors.lastname: Nelson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D015992:Body Mass Index; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary*; D002369:Castration; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen